The Quantellect read.As of Nov 19, 2026, 8 active firms cover Abcellera Biologics Inc: 7 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $9.00 to $30.00 (about 3.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $15.13 sits 37% above the current $11.02. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 7 over recent months. On the fundamentals, the Street sees revenue growth near -57% this year and -3% next, consensus EPS building from about $-0.19 next quarter toward $-0.71 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 active firms
Buy
Strong Buy00%
Buy788%
Neutral113%
Sell00%
Strong Sell00%
Based on 8 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$15.13
+37.3% upside
Average target across 8 active firms as of Nov 19, 2026 vs $11.02 current
Highest Target$30.00
Average Target$15.13
Lowest Target$9.00
Detailed analyst forecasts for ABCL
Showing 1–8 of 8 named analysts shown · 8 active firms in the rating projection
As of Nov 19, 2026, 7 of 8 active firms rate ABCL a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ABCL EPS & revenue forecast
EPS · NEXT QUARTER
$-0.19
Range $-0.21 – $-0.17 · 3 analysts · +33% YoY
Next period, 3 analysts expect Abcellera Biologics Inc to earn $-0.19 a share (range $-0.21 – $-0.17), versus $-0.14 a year earlier. Full-year consensus is $-0.61, growing to $-0.71 the year after.
REVENUE · NEXT QUARTER
$11.2M
Range $7.3M – $15.7M · 3 analysts · -14% YoY
Revenue is expected to reach $11.2M (range $7.3M – $15.7M), -14.0% year-over-year. Full-year consensus is $31.5M, rising to $36.5M next year.
Top analysts covering Abcellera Biologics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ABCL.
#1
Brian Cheng
JP Morgan · Rank #87
Buy
$17.00+54.3% to target
Overall win rate
51%
+ Follow
#2
Roger Song
Jefferies · Rank #122
Buy
$21.00+90.6% to target
Overall win rate
43%
+ Follow
#3
RW
Robert Wasserman
Benchmark · Rank #388
Buy
$11.00-0.2% to target
Overall win rate
41%
+ Follow
#4
SW
Stephen Willey
Stifel · Rank #474
Buy
$9.00-18.3% to target
Overall win rate
29%
+ Follow
#5
Scott Schoenhaus
Keybanc · Rank #540
Buy
$10.00-9.3% to target
Overall win rate
30%
+ Follow
ABCL stock forecast FAQ
What is ABCL's average 12-month price target?+
The 8 active firms with a live target average $15.13 for Abcellera Biologics Inc over the next 12 months, ranging from a $30.00 high to a $9.00 low, as of Nov 19, 2026.
Is ABCL stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 8 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ABCL?+
The Street-high target is $30.00 (Truist Securities), and the Street-low is $9.00 (Stifel). The average of all 8 active-firm targets is $15.13.
How many active Wall Street firms cover ABCL?+
8 active firms have a recognized rating on Abcellera Biologics Inc as of Nov 19, 2026, and 8 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ABCL?+
Among analysts who currently cover ABCL, Brian Cheng of JP Morgan has the strongest overall Quantellect track record (Rank #87). Their current call is Buy with a $17.00 target.
What is Abcellera Biologics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.19 per share (range $-0.21 – $-0.17) across 3 analysts. Full-year EPS is projected at $-0.61, rising to $-0.71 the following year.
How much revenue is Abcellera Biologics Inc expected to report next quarter?+
Consensus revenue is $11.2M (range $7.3M – $15.7M). Full-year revenue is projected at $31.5M, growing to $36.5M next year.
Have analysts been upgrading or downgrading ABCL lately?+
As of Nov 19, 2026, 7 of 8 active firms rate ABCL a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ABCL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.